Also known as Olumiant.
EBGLYSS shows durable control, less maintenance dosing and reduced topical use; TOGETHER‑PsO biomarker data assess Taltz+Zepbound vs Taltz; Olumiant pediatric alopecia areata results also included.
Oral baricitinib showed substantial scalp, eyebrow and eyelash regrowth in a Phase 3 pediatric trial; 4 mg and 2 mg doses outperformed placebo at Week 36.
CHMP backs Olumiant for severe alopecia areata in adolescents, based on Phase 3 study showing 42% achieved 80% scalp hair coverage at 36 weeks. Awaiting European Commission decision.
